RU2008138475A - METHOD FOR PRODUCING COMPOSITIONS OF THE NEW 2 - [(2,6-dichlorophenyl) amino] benzene acetic acid carboxymethyl ester or 2- [2- [2- (2,6-dichlorophenyl) amino] FENILATSETOKSIUKSUSNOY ACID AND METHOD OF USE - Google Patents
METHOD FOR PRODUCING COMPOSITIONS OF THE NEW 2 - [(2,6-dichlorophenyl) amino] benzene acetic acid carboxymethyl ester or 2- [2- [2- (2,6-dichlorophenyl) amino] FENILATSETOKSIUKSUSNOY ACID AND METHOD OF USE Download PDFInfo
- Publication number
- RU2008138475A RU2008138475A RU2008138475/15A RU2008138475A RU2008138475A RU 2008138475 A RU2008138475 A RU 2008138475A RU 2008138475/15 A RU2008138475/15 A RU 2008138475/15A RU 2008138475 A RU2008138475 A RU 2008138475A RU 2008138475 A RU2008138475 A RU 2008138475A
- Authority
- RU
- Russia
- Prior art keywords
- stable composition
- composition according
- dianhydro
- glucitol
- stable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 28
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 title claims abstract 8
- -1 2,6-dichlorophenyl Chemical group 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- 229960004420 aceclofenac Drugs 0.000 claims abstract 7
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims abstract 6
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract 6
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000002500 effect on skin Effects 0.000 claims abstract 4
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims abstract 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 4
- 239000002904 solvent Substances 0.000 claims abstract 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims abstract 3
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 claims abstract 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 claims abstract 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims abstract 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims abstract 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims abstract 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims abstract 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims abstract 2
- 229930003427 Vitamin E Natural products 0.000 claims abstract 2
- 239000000443 aerosol Substances 0.000 claims abstract 2
- 239000003963 antioxidant agent Substances 0.000 claims abstract 2
- 235000006708 antioxidants Nutrition 0.000 claims abstract 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims abstract 2
- 229960004217 benzyl alcohol Drugs 0.000 claims abstract 2
- 239000002775 capsule Substances 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims abstract 2
- 229940093471 ethyl oleate Drugs 0.000 claims abstract 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims abstract 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940100556 laureth-23 Drugs 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims abstract 2
- 229920002114 octoxynol-9 Polymers 0.000 claims abstract 2
- 229940098514 octoxynol-9 Drugs 0.000 claims abstract 2
- 235000021400 peanut butter Nutrition 0.000 claims abstract 2
- 229920001983 poloxamer Polymers 0.000 claims abstract 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 claims abstract 2
- 239000006215 rectal suppository Substances 0.000 claims abstract 2
- 239000000050 smooth muscle relaxant Substances 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims abstract 2
- 235000019165 vitamin E Nutrition 0.000 claims abstract 2
- 229940046009 vitamin E Drugs 0.000 claims abstract 2
- 239000011709 vitamin E Substances 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- WNWBIDPJHFYYLM-UHFFFAOYSA-K iron(3+);prop-2-enoate Chemical group [Fe+3].[O-]C(=O)C=C.[O-]C(=O)C=C.[O-]C(=O)C=C WNWBIDPJHFYYLM-UHFFFAOYSA-K 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 239000002826 coolant Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229960003704 framycetin Drugs 0.000 claims 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- RPMJPANFKPDXFA-UHFFFAOYSA-N n-butyl-1,2,3,4-tetrahydroacridin-1-amine;hydron;chloride Chemical compound Cl.C1=CC=C2C=C3C(NCCCC)CCCC3=NC2=C1 RPMJPANFKPDXFA-UHFFFAOYSA-N 0.000 claims 1
- 229940124641 pain reliever Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Стабильная композиция, включающая ацеклофенак и 2,5-ди-O-мeтил-1,4:3,6-диангидро-D-глюцитол или высшие алкильные производные 2,5-ди-О-арил-1,4:3,6-диангидро-D-глюцитола как растворителя с другими наполнителями или без других наполнителей. ! 2. Стабильная композиция по п.1, где ацеклофенак присутствует в количестве от около 1 до 250 мг на мл 2,5-ди-O-метил-1,4:3,6-диангидро-D-глюцитола или высших алкильных производных 2,5-ди-О-арил-1,4:3,6-диангидро-D-глюцитола. ! 3. Стабильная композиция по п.1, где другие наполнители, когда присутствуют, выбраны из бензилового спирта, арахисового масла, этилолеата, диметилацетамида и лютрола 868, PEG (полиэтиленгликоль) 20 моноолеата, полисорбата 80, PEG 20 глицерол монолаурата, октоксинола 9, лаурета 23. ! 4. Стабильная композиция по любому из пп.1-3 в форме, выбранной из парентеральной, оральной, назальной, кожной, офтальмологической. ! 5. Стабильная композиция по п.4, где парентеральная форма включает антиоксиданты, выбранные из витамина Е, его производных, ВНТ (бутилированный гидрокситолуол), ВНА (бутилированный гидроксианизол), аскорбилпальмитата и подобного. ! 6. Стабильная композиция по п.4, где оральная форма выбрана из капсулы, таблетки, жидкости. ! 7. Стабильная композиция по п.4, где назальные формы включают селективное ингаляционное средство гидрофторалкан (HFA), адаптированное для доставки соответствующих дозированных производных. ! 8. Стабильная композиция по п.4, где дермальные формы выбраны из шарикового апликатора, ректальных суппозиториев, зубного раствора, геля и аэрозоля. ! 9. Стабильная композиция по п.8, где дермальные формы включают воду и другие соединения, выбранные из релаксанта гладких мышц, болеутоля 1. A stable composition comprising aceclofenac and 2,5-di-O-methyl-1,4: 3,6-dianhydro-D-glucitol or higher alkyl derivatives of 2,5-di-O-aryl-1,4: 3 , 6-Dianhydro-D-glucitol as a solvent with or without other excipients. ! 2. The stable composition according to claim 1, where aceclofenac is present in an amount of from about 1 to 250 mg per ml of 2,5-di-O-methyl-1,4: 3,6-dianhydro-D-glucitol or higher alkyl derivatives 2 5-di-O-aryl-1,4: 3,6-dianhydro-D-glucitol. ! 3. The stable composition according to claim 1, where other excipients, when present, are selected from benzyl alcohol, peanut butter, ethyl oleate, dimethylacetamide and lutrol 868, PEG (polyethylene glycol) 20 monooleate, polysorbate 80, PEG 20 glycerol monolaurate, octoxynol 9, laureth 23.! 4. A stable composition according to any one of claims 1 to 3 in a form selected from parenteral, oral, nasal, skin, ophthalmic. ! 5. The stable composition according to claim 4, where the parenteral form includes antioxidants selected from vitamin E, its derivatives, BHT (bottled hydroxytoluene), BHA (bottled hydroxyanisole), ascorbyl palmitate and the like. ! 6. The stable composition according to claim 4, where the oral form is selected from a capsule, tablet, liquid. ! 7. The stable composition according to claim 4, where the nasal forms include a selective inhaled agent hydrofluoroalkane (HFA), adapted for the delivery of the corresponding dosage derivatives. ! 8. The stable composition according to claim 4, where the dermal form is selected from a ball applicator, rectal suppositories, dental solution, gel and aerosol. ! 9. The stable composition of claim 8, where the dermal forms include water and other compounds selected from a smooth muscle relaxant, painkiller
Claims (18)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN295MU2006 | 2006-03-01 | ||
| IN295/MUM/2006 | 2006-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008138475A true RU2008138475A (en) | 2010-04-10 |
Family
ID=38459446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008138475/15A RU2008138475A (en) | 2006-03-01 | 2007-02-28 | METHOD FOR PRODUCING COMPOSITIONS OF THE NEW 2 - [(2,6-dichlorophenyl) amino] benzene acetic acid carboxymethyl ester or 2- [2- [2- (2,6-dichlorophenyl) amino] FENILATSETOKSIUKSUSNOY ACID AND METHOD OF USE |
Country Status (3)
| Country | Link |
|---|---|
| BR (1) | BRPI0708386A2 (en) |
| RU (1) | RU2008138475A (en) |
| WO (1) | WO2007099559A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734852B2 (en) * | 2011-11-30 | 2014-05-27 | Manu Chaudhary | Parenteral controlled release formulations of NSAID's |
| US20170360718A1 (en) * | 2016-06-01 | 2017-12-21 | St. Renatus, Llc | Intranasal dental anesthetic |
| WO2020036478A2 (en) * | 2018-08-13 | 2020-02-20 | AMÉZCUA AMÉZCUA, Federico | Synergistic pharmaceutical composition comprising aceclofenac and betamethasone for the treatment of pain in localised forms of rheumatic illnesses |
-
2007
- 2007-02-28 RU RU2008138475/15A patent/RU2008138475A/en not_active Application Discontinuation
- 2007-02-28 WO PCT/IN2007/000078 patent/WO2007099559A2/en not_active Ceased
- 2007-02-28 BR BRPI0708386-6A patent/BRPI0708386A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007099559A2 (en) | 2007-09-07 |
| WO2007099559A9 (en) | 2009-08-20 |
| WO2007099559A8 (en) | 2008-05-08 |
| BRPI0708386A2 (en) | 2011-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003233653B2 (en) | Compositions and method for transmucosal drug delivery and cryoprotection | |
| CN101790370B (en) | A novel non-aqueous topical solution of diclofenac and process for preparing the same | |
| CN115916184A (en) | Transdermal and/or topical pharmaceutical formulations containing cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain | |
| JP2019001824A (en) | Polyorthoester and composition of aprotic solvent | |
| US11413283B2 (en) | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof | |
| MX2012009838A (en) | PHARMACEUTICAL COMPOSITIONS OF THE ESPIRO-OXINDOL COMPOUND FOR TOPICAL ADMINISTRATION AND ITS USES AS THERAPEUTIC AGENTS. | |
| CN101478952A (en) | Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof | |
| KR20080071185A (en) | Pharmaceutical composition comprising buprenorphine | |
| EP4041209A1 (en) | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders | |
| IL315573A (en) | Preparations, methods and systems for the treatment of skin disorders | |
| KR20200051573A (en) | Apparatus and method for the treatment of body surface disorders | |
| AU2019258677B2 (en) | Topical pharmaceutical composition for treatment of anal fissures and hemorrhoids | |
| JP2011507826A (en) | Pharmaceutical formulation containing tolperisone | |
| CN105561288A (en) | Alanyl-glutamine-containing bioadhesive hydrogel and membrane | |
| US11826330B2 (en) | Compounded compositions and methods for treating pain | |
| RU2008138475A (en) | METHOD FOR PRODUCING COMPOSITIONS OF THE NEW 2 - [(2,6-dichlorophenyl) amino] benzene acetic acid carboxymethyl ester or 2- [2- [2- (2,6-dichlorophenyl) amino] FENILATSETOKSIUKSUSNOY ACID AND METHOD OF USE | |
| TWI884917B (en) | Compositions and dosage forms for oral delivery | |
| US20060286172A1 (en) | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same | |
| CA2869377C (en) | Fulvestrant formulations | |
| WO2022215030A1 (en) | Pharmaceutical composition and method for treating seizure disorders | |
| EP1679296A4 (en) | Ether derivative | |
| CN100364543C (en) | Topical preparations for inhibiting keloid formation | |
| KR20230026449A (en) | Topical formulations of (1S)-1-phenyl-2-pyridin-2-yletanamine | |
| CN1432410A (en) | External prepn for stopping skin pain quickly | |
| WO2025217435A1 (en) | Pharmaceutical formulations containing phenylbutyrate and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110502 |